Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.

---

Copy For Citation

ZOGHİ M., Kaya H., ÇAVUŞOĞLU Y., Aksakal E., Demir S., Yucel C., ...More

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, vol.44, no.6, pp.457-65, 2016 (Scopus)

• Publication Type: Article / Article
• Volume: 44 Issue: 6
• Publication Date: 2016
• Doi Number: 10.5543/tkda.2016.10733
• Journal Name: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
• Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
• Page Numbers: pp.457-65
• Keywords: Functional capacity, heart failure, medical adherence, socioeconomic status, IDIOPATHIC DILATED CARDIOMYOPATHY, BETA(1)-ADRENERGIC RECEPTOR, ELDERLY-PATIENTS, ASSOCIATION, METOPROLOL, IMPACT, CARVEDILOL, ALPHA(2C)DEL322-325, PHARMACOKINETICS, RECOMMENDATIONS
• Dokuz Eylül University Affiliated: Yes

Abstract

Objective: The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy.